naveglitazar

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Non-Insulin-Dependent

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Trial Timeline

— → —

About naveglitazar

naveglitazar is a phase 2 stage product being developed by Eli Lilly for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00065312. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00065312Phase 2Completed